GSK and MMV report positive headline results from two Phase III trials of tafenoquine

GlaxoSmithKline (GSK) and Swiss-based Medicines for Malaria Venture (MMV) have reported positive headline results from two Phase III clinical trials of tafenoquine to prevent a relapse of malaria caused by Plasmodium vivax (P. vivax).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news